# Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C

Study · id `cardio:ct-nct03814187` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03814187](<https://clinicaltrials.gov/study/NCT03814187>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03814187

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 3275 participants.

## Technical summary

Registry record NCT03814187. Allocation not applicable; no masking; primary purpose treatment. Start 2019-04-16 (actual); primary completion 2023-02-13 (actual). Results posted on 2024-03-06.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 3275 participants (enrolled count; ClinicalTrials.gov record NCT03814187, source copy `cardio:ctgov-nct03814187-2024-03-06`, retrieved 2026-10-31)
- Started: 2019-04-16 (actual) (ClinicalTrials.gov record NCT03814187, source copy `cardio:ctgov-nct03814187-2024-03-06`, retrieved 2026-10-31)
- Primary completion: 2023-02-13 (actual) (ClinicalTrials.gov record NCT03814187, source copy `cardio:ctgov-nct03814187-2024-03-06`, retrieved 2026-10-31)
- Completion: 2023-02-13 (actual) (ClinicalTrials.gov record NCT03814187, source copy `cardio:ctgov-nct03814187-2024-03-06`, retrieved 2026-10-31)
- Results first posted: 2024-03-06 (ClinicalTrials.gov record NCT03814187, source copy `cardio:ctgov-nct03814187-2024-03-06`, retrieved 2026-10-31)
- Countries: United States; Canada; Czechia; Denmark; Germany; Hungary; Netherlands; Poland; South Africa; Spain; Sweden; Ukraine; United Kingdom (ClinicalTrials.gov record NCT03814187, source copy `cardio:ctgov-nct03814187-2024-03-06`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03814187-2024-03-06`, retrieved 2026-10-31)

## The registry's words

- Brief title: Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C
- Acronym: ORION-8
- Condition: ASCVD
- Condition: Elevated Cholesterol
- Condition: Heterozygous Familial Hypercholesterolemia
- Condition: Homozygous Familial Hypercholesterolemia
- Intervention (Drug): Inclisiran Sodium
- Lead sponsor: Novartis Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: Familial hypercholesterolemia (`cardio:familial-hypercholesterolemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Inclisiran (`cardio:inclisiran`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial (`cardio:pubmed-38753448`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 4be60d494dc347868d1d617d1fd2d03bd6096d4fc648e364ba6b66936ad5cedb
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
